At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 507 enrolled
Drug / intervention
Risankizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
In Brief
A Phase 3 clinical trial evaluating Risankizumab and Placebo for Psoriasis. Completed, enrolled 507 participants.
Detailed Summary
This was a multinational, multicenter, randomized, double-blind, placebo controlled study with randomized withdrawal and retreatment, evaluating the safety and efficacy of risankizumab 150 mg subcutaneous (SC) in participants with moderate to severe chronic plaque psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
Countries--
CollaboratorsBoehringer Ingelheim
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 2016
Enrollment StartFeb 2016
Primary CompletionAug 2017
Study CompletionJul 2018
TodayJul 2026
First PostedFeb 3, 2016
Enrollment StartFeb 29, 2016
Primary CompletionAug 2, 2017
Study CompletionJul 26, 2018
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 10.4 years ago
Interventions
Risankizumabdrug
Risankizumab administered by subcutaneous injection
Placebodrug
Placebo for risankizumab administered by subcutaneous injection